Qtrex Quantum Ltd. · NASDAQ:QTEX

Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (August 2022)

17 slides from Qtrex Quantum's investor presentation, Aug 8, 2022

Slide 2: Forward looking - Statements
Forward looking - Statements This presentation of Inspira TM Technologies Oxy B . H . N . Ltd . (“Inspira Technologies” or the “Company”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities law . Words such as “expects,” “in
Slide 3: Note on Inspira ART naming
3 3 * The Inspira Ρ ART and the ART presented in this presentation are both referring to the Inspira Ρ ART Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved
Slide 4: We need to unlock your dependency on invasive mechanical ventilation
4 4 We need to unlock your dependency on invasive mechanical ventilation Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved
Slide 6: Respiratory Failure Multiple Trends Propelling the Market in the Coming Years
Respiratory Failure Multiple Trends Propelling the Market in the Coming Years Respiratory failure is a serious medical condition that develops when the lungs cannot get sufficient oxygen into the blood. Buildup of carbon dioxide can also damage the tissues and organs. Acute respiratory failure can o
Slide 7: Inspira ART video
7 7 * The Inspira ART and the ART presented in this presentation are both referring to the Inspira ART. The Inspira ART has not been cleared or approved or cleared by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Play Video Copyright © 2018 - 2022 Inspira Technologie
Slide 8: Risks and complications of mechanical ventilation
1. Am J Respir Crit Care Med Vol. 196, P3 - 4, 2017. ATS Patient Education Series © 2017 American Thoracic Society 2. Diling Wu et al. Frontiers in pharmacology MINI REVIEW published: 09 May 2019. doi: 10.3389/fphar.2019.00482 3. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hos
Slide 9: Augmented Respiratory Technology (Inspira ART)
9 9 o Aims to reduce the need for invasive mechanical ventilation (IMV) with the potential to reduce risks, complications and high costs o Targets for patient to remain awake & spontaneously breathing o Will be designed to utilize direct blood oxygenation to boost patient saturation levels within mi
Slide 10: Business Model and Go To Market Strategy
Inspira ART system Disposable kit + □ Clinical studies at Leading World - Renowned Hospital □ Food and Drug Administration ( FDA) Regulatory Process □ Reimbursement Coding □ Strategic collaboration with industry leaders (Medical Device Companies or Other) □ Distribution Agreements Clinical Activity
Slide 11: Market Opportunity By Product
* To - date the Inspira Ρ ART System, ALICE Ρ Device and HYLA Ρ Blood Sensor have not been tested or used on humans and are subject to the regulator’s approvals or clearance. Timelines and milestones may be subject to change. 11 Market Opportunity By Product * ALICE TM Device Life Support - The Alic
Slide 12: Planned Milestones 2022 - 2023
The milestones and timelines are subject to change. There is no guarantee as to the success of any trial. In addition, there is inherent risk and variability in the overall regulatory process. Approval by the FDA may not be granted, or the FDA may require different study parameters from those that a
Slide 13: Inspira Cash Management
Company $12 million $9.4 million $16 million incorporation Raised prior to IPO: Including funds from Israeli Innovation Authority Raised at initial public offering on NASDAQ Warrants exercised at $5.50 per share Feb.2018 2019 up to Q1 - 2021 Jul. 2021 Oct. 2021 $21.7 million, Cash on hand as of Marc
Slide 14: Experienced Leadership Team
Prof. Benad Goldwasser, MD, MBA Chairman Multiple well - known industry exits Dagi Ben - Noon, BSc Co - Founder, Director & CEO Co - founder of Nano Dimension Nasdaq: NNMD 14 Daniella Yeheskely - Hayon, PhD CTO 13 yrs development experience Joe Hayon, MBA Co - Founder, Director, President & CFO M&A
Slide 15: Scientific Advisory Board
Dr. Yigal Kasif, MD ECMO Advisor Chairman of the Israel ECMO Society. Director of ECMO program at Sheba Medical Center. Surgeon, Specializing in Adult Cardiac Surgery, Heart Transplantation and Assist Devices. Dr. Stephan Ledot Intensivist & ECMO Advisor World - renowned expert in critical care, ECM
Slide 16: You Need to be Conscious of Your Potential Alternatives
16 You Need to be Conscious of Your Potential Alternatives * The Inspira ART and the ART presented in this presentation are both referring to the Inspira ART. To - date the Inspira ART System has not been tested or used on humans and is subject to the regulator’s approvals or clearances. Copyright ©

Inspira Technologies OXY B.H.N. — Investor Presentation (August 2022) on 6ix

Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (August 2022)

Slide 1: Investor Presentation August 2022

Slide 2: Forward looking - Statements

Slide 3: Note on Inspira ART naming

Slide 4: We need to unlock your dependency on invasive mechanical ventilation

Slide 5: The Respiratory Gap

Slide 6: Respiratory Failure Multiple Trends Propelling the Market in the Coming Years

Slide 7: Inspira ART video

Slide 8: Risks and complications of mechanical ventilation

Slide 9: Augmented Respiratory Technology (Inspira ART)

Slide 10: Business Model and Go To Market Strategy

Slide 11: Market Opportunity By Product

Slide 12: Planned Milestones 2022 - 2023

Slide 13: Inspira Cash Management

Slide 14: Experienced Leadership Team

Slide 15: Scientific Advisory Board

Slide 16: You Need to be Conscious of Your Potential Alternatives

Slide 17: Thank You